Results 121 to 130 of about 14,850 (194)

Sodium Glucose‐Like Co‐Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis

Respirology Case Reports, Volume 14, Issue 3, March 2026.
Use of sodium glucose‐like co‐transporter 2 inhibitors in people with cystic fibrosis may be considered for glycaemic, renal and cardiac benefits. We described safe, tolerable and effective use in three adults with CF. ABSTRACT Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi ...
Ellie Johnson, Angela Matson, Robyn Cobb, Shanal Kumar   +3 more
wiley   +1 more source

Septic shock from urinary tract infection associated with sodium-glucose cotransporter 2 inhibitor in a high-risk patient with heart failure: A case report. [PDF]

J Int Med Res
Tang Y, Zhang Y, Liu X, Chen G, Yin L, Wu M.   +5 more
europepmc   +1 more source

Effects of Dapagliflozin on Novel Inflammatory Markers in Heart Failure Patients. [PDF]

Cardiol Res Pract
Senoz O, Sezen M.
europepmc   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1915-1923, March 2026.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

Effects of a Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin on Pancreas in Obese Diabetic Mice. [PDF]

In Vivo
Sekikawa R, Uehara H, Uno K, Sasase T, Nakata Y, Mori Y, Shinohara M, Sugimoto M, Ohta T.   +8 more
europepmc   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1956-1971, March 2026.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study. [PDF]

Pharmacoepidemiol Drug Saf
Tamura R, Kim H, Takumi Y, Ishihara M, Kobayashi T, Layton D, Sakamoto K.   +6 more
europepmc   +1 more source

Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2183-2202, March 2026.
Abstract Aims The extent to which the cardiovascular benefits of sodium–glucose co‐transporter 2 inhibitors (SGLT‐2is) and glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) differ by sex remains unclear. This systematic meta‐analysis aimed to investigate sex differences in trial representation and the cardiovascular and kidney efficacy of SGLT‐2is ...
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor K. Kunutsor   +6 more
wiley   +1 more source

The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes

Journal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Childhood obesity has led to an increase in type 2 diabetes (T2D) among youth, with adolescent‐onset T2D showing a rapid decline in β‐cell function compared to adult‐onset cases. While the disease progression is more aggressive in early life, treatment can lead to recovery or remission more often at younger ages.
Iuliana Popescu, Robert C. Bunn, Phil Ray, Kathryn M. Thrailkill, John L. Fowlkes   +4 more
wiley   +1 more source

Sodium-glucose cotransporter 2 inhibitors facilitate cell phenotype conversion of alpha cells through progenitors to beta cells by activating Ppargc1α in diabetic mice. [PDF]

Chin Med J (Engl)
Jiang Y, Wang D, Tao M, Cui X, Li J, Wei T, Yang J, Hong T, Wei R.   +8 more
europepmc   +1 more source